VIP-loaded PLGA as an anti-asthma nanodrug candidate
- 127 Downloads
Poly lactic-co-glycolic acid (PLGA), a biodegradable polymer, can effectively protect encapsulated peptides from enzymatic degradation. PLGA was approved by FDA as a safe drug delivery system suitable for inhalation administration. Vasoactive intestinal peptide (VIP), a 28-amino-acid peptide, displays anti-inflammatory and anti-spasmodic effects, which can be considered as a new therapeutic option to control and treat asthma. Because of in vivo enzymatic degradation of VIP including in the lung, there is a need for an applicable delivery system. In light of this, the purpose of this study was to prepare VIP-loaded PLGA microspheres as a drug delivery system, assuming that the newly-introduced model has the ability to persist for a longer time in respiratory tracts. The PLGA microsphere was produced, and loaded with VIP as an applicable nanodrug system. A series of physiochemical properties were determined, including the morphological characteristics, average size of nanoparticles, electric charge distribution, FTIR spectroscopy absorption, and loading and releasing percentage of the nanodrug. VIP-loaded PLGA exhibited an average size of approximately 550 ± 50 nm. Additionally, the produced microsphere showed 78 % VIP release after 10 h at the pH value corresponding to bronchioalveolar microenvironment (approximately 6.5). In the present study, PLGA was formulated and used as a delivery system for VIP. Taken together, the newly-introduced nanodrug seems to be helpful for the clinical treatment of allergic asthma. PLGA nanoparticles can be considered as a potential efficient delivery system for VIP in the respiratory system.
KeywordsPLGA Vasoactive intestinal peptide Nanodrug
This manuscript was based on a research work performed as a partial fulfillment for PhD degree in medical immunology that was supported by Tarbiat Modares University. The authors also acknowledge Dr. Mehdi Shafiee Ardestani; the Immunology, Asthma and Allergy Research Institute, Children’s Medical Center, Tehran University of Medical Sciences, Tehran, Iran; Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran; Utrecht Institute for Pharmaceutical Sciences, Faculty of Sciences, Utrecht University, Utrecht, Netherlands and Airways Disease Section, National Heart and Lung Institute, Faculty of Medicine, Imperial College London, London, UK.
Compliance with ethical standards
This article does not contain any studies with human participants or animals performed by any of the authors. This study has ethical approval from the Asthma and Allergy Research Institute, Children’s Medical Center, Tehran University of Medical Sciences with No. 412/P/236 and from the Faculty of Medical Sciences, Tarbiat Modares University with No. 52D/6564.
Conflicts of interest
The authors declare that there are no conflicts of interest.
This study was funded by Tarbiat Modares University (52D/313), Utrecht Institute for Pharmaceutical Sciences, Faculty of Sciences, Utrecht University and Immunology, Asthma and Allergy Research Institute, Children’s Medical Center, Tehran University of Medical Sciences (412/P/135).
- Igarashi H, Ito T, Mantey SA et al (2005) Development of simplified vasoactive intestinal peptide analogs with receptor selectivity and stability for human vasoactive intestinal peptide/pituitary adenylate cyclase-activating polypeptide receptors. J Pharmacol Exp Ther 315(1):370–381CrossRefPubMedGoogle Scholar
- Semete B, Booysen L, Lemmer Y, Kalombo L, Katata L, Verschoor J, Swai HS (2010) In vivo evaluation of the biodistribution and safety of PLGA nanoparticles as drug delivery systems. Nanomed: Nanotechnol, Biol Med 6:662–671Google Scholar
- Tseng C-L, Wu SY-H, Wang W-H, Peng C-L, Lin F-H, Lin C-C, Young T-H, Shieh M-J (2008) Targeting efficiency and biodistribution of biotinylated-EGF-conjugated gelatin nanoparticles administered via aerosol delivery in nude mice with lung cancer. Biomaterials 29(20):3014–3022CrossRefPubMedGoogle Scholar
- Ungaro F, d’Angelo I, Ciro C, di Villa Bianca R d’E, Raffaella S, Brunella P, Maria Antonietta T, Agnese M, Maria Immacolata La R, Fabiana Q (2012) Dry powders based on PLGA nanoparticles for pulmonary delivery of antibiotics: modulation of encapsulation efficiency, release rate and lung deposition pattern by hydrophilic polymers. J Control Release 157:149–159CrossRefPubMedGoogle Scholar
- van Noort JM, Bsibsi M, Nacken PJ, Gerritsen WH, Amor S, Holtman IR, Boddeke E, van Ark I, Leusink-Muis T, Folkerts G, Hennink WE, Amidi M (2013) Activation of an immune-regulatory macrophage response and inhibition of lung inflammation in a mouse model of COPD using heat-shock protein alpha B-crystallin-loaded PLGA microparticles. Biomaterials 34:831–840CrossRefPubMedGoogle Scholar